WASHINGTON and SAN DIEGO, Feb. 1, 2012 /PRNewswire-iReach/ -- FirstMark is pleased to announce that it will be exhibiting at the CRT 2012 Conference in Washington D.C. on February 5 – 7. FirstMark will showcase its new cardiovascular diagnostic test PREvent. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant stable CAD. The test is a critical advancement in cardiovascular medicine addressing the unmet need to assess risk of near term MI.
"CRT 2012 is a great opportunity to showcase our new cardiovascular blood test. It also gives us the chance to meet with leading cardiologists from around the country and update them first-hand on our new test, including the very impressive final data. We are proud to be a part of such a key industry event," says Thomas Silberg, President and CEO of GenWay Biotech.
Details about the test's research will be given in an oral presentation at the conference, An Aggregate of 3 Biomarkers Predict Very High Risk of Acute Myocardial Infarction and Death, by Dr. Stephen E. Epstein, Director of the Vascular Biology Laboratory and Executive Director of the Cardiovascular Research Institute, MedStar Health Research Institute at the Washington Hospital Center, 11:35 a.m. Monday, February 6. (Atherosclerosis & HDL Therapy).
About FirstMark PREvent
FirstMark PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction and/or death in patients with suspected or confirmed, insignificant or significant stable CAD. PREvent aggregates three cardiovascular biomarkers that identify the pathways that lead to vulnerable plaque formation. In a clinical study, an annual average of 18.2% of patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with normal biomarker levels. In addition, the multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk subjects from low risk subjects. PREvent distinguishes the top 5% of CAD patients who are at a 5.5 times greater risk of a near term cardiac event, allowing physicians to identify individuals in urgent need of the most aggressive treatment, compliance and monitoring. FirstMark is a Division of GenWay Biotech.
About GenWay Biotech, Inc.
GenWay Biotech, Inc., is comprised of three divisions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay's catalog products and custom services divisions are focused on protein and antibody solutions. GenWay's headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information about GenWay Biotech, please visit GenWayBio.com or FirstMarkPREvent.com.Media Contact:
Deborah Moore GenWay Biotech, Inc., 858-458-0866, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE GenWay Biotech, Inc.|
Copyright©2010 PR Newswire.
All rights reserved